Abstract
Purpose. To describe a case of exudative macular detachment secondary to peripheral exudative chorioretinopathy with a favorable anatomic and visual outcome following treatment with intravitreal bevacizumab. Methods. The medical records of a patient with peripheral exudative chorioretinopathy were reviewed. Results. Macular reattachment was achieved with a corresponding visual acuity improvement that was maintained over an uncomplicated 17-month clinical course. Conclusions. Bevacizumab may be an effective treatment option for exudative macular detachment secondary to peripheral exudative hemorrhagic chorioretinopathy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 506-508 |
| Number of pages | 3 |
| Journal | European Journal of Ophthalmology |
| Volume | 21 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 2011 |
Keywords
- Bevacizumab
- Eccentric disciform degeneration
- Eccentric retinal degeneration
- Extramacular degeneration
- Peripheral exudative hemorrhagic chorioretinopathy
ASJC Scopus subject areas
- Ophthalmology
Fingerprint
Dive into the research topics of 'Regression of serous macular detachment due to peripheral exudative hemorrhagic chorioretinopathy following intravitreal bevacizumab'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS